MX378503B - Alfavirus recombinantes atenuados incapaces de replicarse en mosquitos y usos de estos. - Google Patents
Alfavirus recombinantes atenuados incapaces de replicarse en mosquitos y usos de estos.Info
- Publication number
- MX378503B MX378503B MX2019010530A MX2019010530A MX378503B MX 378503 B MX378503 B MX 378503B MX 2019010530 A MX2019010530 A MX 2019010530A MX 2019010530 A MX2019010530 A MX 2019010530A MX 378503 B MX378503 B MX 378503B
- Authority
- MX
- Mexico
- Prior art keywords
- mosquitoes
- replication
- attenuated recombinant
- incapable
- equine encephalitis
- Prior art date
Links
- 241000255925 Diptera Species 0.000 title abstract 3
- 230000002238 attenuated effect Effects 0.000 title abstract 3
- 230000010076 replication Effects 0.000 title 1
- 241000710929 Alphavirus Species 0.000 abstract 3
- 241001502567 Chikungunya virus Species 0.000 abstract 1
- 241000710945 Eastern equine encephalitis virus Species 0.000 abstract 1
- 241000710959 Venezuelan equine encephalitis virus Species 0.000 abstract 1
- 241000710951 Western equine encephalitis virus Species 0.000 abstract 1
- 230000005540 biological transmission Effects 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000003362 replicative effect Effects 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/04—Inactivation or attenuation; Producing viral sub-units
- C12N7/045—Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36161—Methods of inactivation or attenuation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36171—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6222908P | 2008-01-24 | 2008-01-24 | |
| PCT/US2009/000458 WO2009131604A2 (en) | 2008-01-24 | 2009-01-23 | Attenuated recombinant alphaviruses incapable of replicating in mosquitoes and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2019010530A MX2019010530A (es) | 2019-10-15 |
| MX378503B true MX378503B (es) | 2025-03-11 |
Family
ID=41217313
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019010530A MX378503B (es) | 2008-01-24 | 2009-01-23 | Alfavirus recombinantes atenuados incapaces de replicarse en mosquitos y usos de estos. |
| MX2014010258A MX367792B (es) | 2008-01-24 | 2009-01-23 | Alfavirus recombinantes atenuados incapaces de replicarse en mosquitos y usos de estos. |
| MX2010007989A MX2010007989A (es) | 2008-01-24 | 2009-01-23 | Alfavirus recombinantes atenuados incapaces de replicarse en mosquitos y usos de estos. |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014010258A MX367792B (es) | 2008-01-24 | 2009-01-23 | Alfavirus recombinantes atenuados incapaces de replicarse en mosquitos y usos de estos. |
| MX2010007989A MX2010007989A (es) | 2008-01-24 | 2009-01-23 | Alfavirus recombinantes atenuados incapaces de replicarse en mosquitos y usos de estos. |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US8426188B2 (https=) |
| EP (2) | EP3085787B1 (https=) |
| JP (1) | JP5758632B2 (https=) |
| KR (2) | KR101668849B1 (https=) |
| CN (1) | CN102083986B (https=) |
| AU (1) | AU2009238667A1 (https=) |
| CA (2) | CA2910235C (https=) |
| CO (1) | CO6290702A2 (https=) |
| IL (2) | IL207167A (https=) |
| MX (3) | MX378503B (https=) |
| MY (1) | MY178870A (https=) |
| NZ (2) | NZ603790A (https=) |
| SG (2) | SG187513A1 (https=) |
| WO (1) | WO2009131604A2 (https=) |
| ZA (1) | ZA201005943B (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8460913B2 (en) * | 2007-06-21 | 2013-06-11 | Alpha Vax, Inc. | Promoterless cassettes for expression of alpha virus structural proteins |
| KR101668849B1 (ko) | 2008-01-24 | 2016-10-24 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 모기에서 복제 불가능한 약독화된 재조합 알파바이러스 및 그의 용도 |
| US8961995B2 (en) | 2012-09-20 | 2015-02-24 | Uab Research Foundation | Methods and compositions for alphavirus replicons |
| BR112015006840A2 (pt) | 2012-09-27 | 2017-11-21 | Res Found Dev | vírus chikungunya atenuado |
| AP2015008733A0 (en) | 2013-03-14 | 2015-09-30 | Takeda Vaccines Inc | Compositions and methods for live, attenuated alphavirus formulations |
| PE20190178A1 (es) * | 2016-03-31 | 2019-02-01 | Takeda Vaccines Inc | Constructos de alfavirus vivo atenuado y metodos y usos de los mismos |
| US11090384B2 (en) * | 2016-05-27 | 2021-08-17 | Griffith University | Arthrogenic alphavirus vaccine |
| EP3634449A4 (en) | 2017-05-08 | 2021-03-17 | Gritstone Oncology, Inc. | ALPHAVIRUS NEOANTIGEN VECTORS |
| SG11202005792RA (en) | 2017-12-20 | 2020-07-29 | Vlp Therapeutics Llc | Alphavirus replicon particle |
| US20210268098A1 (en) * | 2018-08-03 | 2021-09-02 | Uab Research Foundation | Methods and compositions for alphavirus vaccine |
| CN109536464B (zh) * | 2018-12-10 | 2022-06-10 | 中国科学院武汉病毒研究所 | 一种缺失衣壳蛋白基因的基孔肯雅病毒感染性克隆及构建方法和在制备减毒疫苗中的应用 |
| MX2021014525A (es) | 2019-05-30 | 2022-03-17 | Gritstone Bio Inc | Adenovirus modificados. |
| MX2022007905A (es) | 2019-12-31 | 2022-08-25 | Elixirgen Therapeutics Inc | Administracion transitoria basada en temperatura de acidos nucleicos y proteinas a celulas y tejidos. |
| CN116438308A (zh) | 2020-08-06 | 2023-07-14 | 磨石生物公司 | 多表位疫苗盒 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6451592B1 (en) * | 1996-04-05 | 2002-09-17 | Chiron Corporation | Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis |
| CA2327189A1 (en) * | 2000-12-21 | 2002-06-21 | The Minister Of National Defence | Novel dna-based vaccine against the encephalitis alphaviruses |
| US7442381B2 (en) | 2003-03-20 | 2008-10-28 | Alphavax, Inc. | Alphavirus replicons and helper constructs |
| EP1658744A4 (en) | 2004-07-30 | 2006-09-27 | Research In Motion Ltd | METHOD AND SYSTEM FOR COORDINATING THE PARAMETERS OF A DEVICE BETWEEN A COMMUNICATIONS CLIENT AND HOST DEVICE |
| US7332322B2 (en) | 2004-09-14 | 2008-02-19 | Ilya Frolov | Venezuelan equine encephalitis virus replicons with adaptive mutations in the genome and uses thereof |
| CA2579507C (en) | 2006-03-15 | 2017-06-13 | Institut Pasteur | Novel isolated and purified strains of chikungunya virus and polynucleotides and polypeptides sequences, diagnostic and immunogenical uses thereof |
| KR101668849B1 (ko) | 2008-01-24 | 2016-10-24 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 모기에서 복제 불가능한 약독화된 재조합 알파바이러스 및 그의 용도 |
-
2009
- 2009-01-23 KR KR1020107018777A patent/KR101668849B1/ko not_active Expired - Fee Related
- 2009-01-23 KR KR1020167029024A patent/KR101913790B1/ko not_active Expired - Fee Related
- 2009-01-23 MX MX2019010530A patent/MX378503B/es unknown
- 2009-01-23 AU AU2009238667A patent/AU2009238667A1/en not_active Abandoned
- 2009-01-23 CA CA2910235A patent/CA2910235C/en not_active Expired - Fee Related
- 2009-01-23 SG SG2013005624A patent/SG187513A1/en unknown
- 2009-01-23 SG SG10201606111XA patent/SG10201606111XA/en unknown
- 2009-01-23 MX MX2014010258A patent/MX367792B/es unknown
- 2009-01-23 EP EP16000617.7A patent/EP3085787B1/en not_active Not-in-force
- 2009-01-23 JP JP2010544350A patent/JP5758632B2/ja not_active Expired - Fee Related
- 2009-01-23 CA CA2713165A patent/CA2713165C/en not_active Expired - Fee Related
- 2009-01-23 NZ NZ603790A patent/NZ603790A/en not_active IP Right Cessation
- 2009-01-23 MY MYPI2010003463A patent/MY178870A/en unknown
- 2009-01-23 CN CN200980110510.1A patent/CN102083986B/zh not_active Expired - Fee Related
- 2009-01-23 WO PCT/US2009/000458 patent/WO2009131604A2/en not_active Ceased
- 2009-01-23 MX MX2010007989A patent/MX2010007989A/es active IP Right Grant
- 2009-01-23 NZ NZ587502A patent/NZ587502A/xx not_active IP Right Cessation
- 2009-01-23 EP EP09735287.6A patent/EP2250269B1/en not_active Not-in-force
-
2010
- 2010-07-22 IL IL207167A patent/IL207167A/en active IP Right Grant
- 2010-07-23 US US12/804,535 patent/US8426188B2/en active Active
- 2010-08-20 ZA ZA2010/05943A patent/ZA201005943B/en unknown
- 2010-08-20 CO CO10102866A patent/CO6290702A2/es active IP Right Grant
-
2013
- 2013-04-03 US US13/855,960 patent/US9580690B2/en active Active
-
2014
- 2014-04-09 IL IL232032A patent/IL232032A0/en unknown
-
2017
- 2017-02-27 US US15/443,364 patent/US10533186B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX378503B (es) | Alfavirus recombinantes atenuados incapaces de replicarse en mosquitos y usos de estos. | |
| PH12018502120A1 (en) | Live attenuated alphavirus constructs and methods and uses thereof | |
| MX375431B (es) | Virus de la enfermedad de newcastle y usos de los mismos. | |
| CL2011003273A1 (es) | Antígeno del virus respiratorio sincicial (vrs) recombinante, que comprende un polipéptido de proteína f soluble con una modificación que altera su glicosilación y que a su vez comprende un dominio f1 y un dominio f2 de proteína f de vrs; composición inmunogénica que lo comprende; ácido nucleico que lo codifica; vector; célula hospedera; método para producir dicho antígeno del vrs; y su uso para tratar una infección de vrs. | |
| MX387396B (es) | Un poliepitope quimerico de virus de dengue compuesto por fragmentos de proteinas no estructurales y su uso en una composicion inmunogenica contra infeccion de virus de dengue. | |
| MX2018011534A (es) | Metodos para transfectar plantas y para reducir eventos de integracion aleatoria. | |
| MX2020005554A (es) | Vacunas y composiciones inmunogenas para zika y metodos para usarlas. | |
| WO2019098759A3 (ko) | 형질전환된 인간세포 및 이의 용도 | |
| MX387420B (es) | Producción de virus en cultivos celulares. | |
| ZA201900070B (en) | Antibodies with low immunogenicity and uses thereof | |
| MX385886B (es) | Macromoleculas estrellas compatibles con tensoactivos. | |
| PH12015502666A1 (en) | Dengue virus vaccine compositions and methods of use thereof | |
| NZ631012A (en) | Compositions and methods for live, attenuated alphavirus formulations | |
| MY166879A (en) | Attenuated swine influenza vaccines and methods of making and use thereof | |
| EA201990483A1 (ru) | Композиции, содержащие конкретные поверхностно-активные вещества и высокие содержания глицерина | |
| MY190399A (en) | A composition comprising cistanche and ginkgo extracts, the composition useful for improving memory of a subject | |
| Trierveiler-Pereira | Phalloid fungi (Phallales) of Brazil | |
| BR112015023635A8 (pt) | Composições e métodos para construtos quiméricos de vírus da dengue em vacinas | |
| Prohnenko | “RUSHED OVER THE GREAT MOUNTAINS AND STARTED FIGHTING SLAVS WHO LIVED THERE...”: THE PROBLEM OF THE NORTHERN WAY OF HUNGARIAN MIGRATION OVER THE CARPATHIANS | |
| CL2017000073A1 (es) | Agente con propiedades antivirales para prevenir o tratar a individuos expuestos a un virus de la familia birnaviridae | |
| WO2012056387A3 (en) | A dermaceutical gel made using sodium fusidate and a process to make it |